Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

• Status: Active, not recruiting
• Trial end date: 2026-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose of the study :

To evaluate the antitumoral effect of two therapeutic procedures and to evaluate their respective toxicity on the CNS.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut Curie
• Collaborators: Amgen; Hoffmann-La Roche; Ministry of Health, France; Pierre Fabre Laboratories
• Treatments: Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Methotrexate; Prednisone; Thiotepa

Criteria

Inclusion Criteria:

• Histopathologically or cytologically proven diagnostic of Primary CNS lymphoma

• All histological types of non-Hodgkin's lymphoma, except MALT

• Age > 18 and < 60 ans.

• Negative for HIV, HCV and HBV

• Written informed consent -

Exclusion Criteria:

• Age < 18 or > 60 ans

• Isolated intra-ocular lymphoma

• Previous history of indolent lymphoma

• Previous chemotherapy or radiotherapy for PCNSL

• Isolated CNS relapse of systemic NHL

• Previous history of cancer in the last 5 years, except basocellular carcinoma and non invasive cervix cancer

• Renal insufficiency or creatinin clearance < 60 ml/min

• Liver enzymes > 3N.

• Platelets < 100 000/mm3 or neutrophils < 1500/mm3)

• Previous history of organ transplantation or other cause of severe immunodeficiency

• Pregnancy or active sexual women with no contraception

• Unable to follow the protocol for any reason